Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present AstraZeneca Plc (NYSE: AZN).

Full DD Report for AZN

You must become a subscriber to view this report.


Recent News from (NYSE: AZN)

NewLink Genetics: Explicating The Changing Fundamentals Of A Potential Comeback
We all are learning, modifying, or destroying ideas all the time. Rapid destruction of your ideas when the time is right is one of the most valuable qualities you can acquire. You must force yourself to consider arguments on the other side. - Charlie Munger NewLink Genetics (NASDAQ: NLNK...
Source: SeekingAlpha
Date: May, 17 2018 05:16
Biotechs perk up ahead of ASCO abstract drop
The SPDR S&P Biotech ETF ( XBI +1.1% ) is up  1%  as investors ramp up buying ahead of the abstract drop for the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 1 - 5. More news on: SPDR Biotech ETF, Celgene Corporation, bluebird bio, Inc., He...
Source: SeekingAlpha
Date: May, 16 2018 12:56
AstraZeneca- Blockbuster Potential in Lung Cancer
Lung cancer remains the leading cause of cancer death and the most common form of the disease detected every year, accounting for more new cases than breast, colon and prostate cancers put together, exclaims Todd Shaver , growth stock specialist and editor of BullMarket.com . As a result...
Source: MoneyShow.com
Date: May, 16 2018 01:00
Kiniksa Pharmaceuticals Aims For $126 Million U.S. IPO
Quick Take Kiniksa Pharmaceuticals ( KNSA ) intends to raise $126 million in a U.S. IPO of its Class A common stock, according to an amended S-1/A registration statement . The company is developing a pipeline of drug treatments for autoinflammatory and autoimmune diseases. KNSA is mak...
Source: SeekingAlpha
Date: May, 15 2018 12:38
Free Stock Performance Review on Pfizer and Three More Drug Makers' Stocks
Stock Research Monitor: AZN, CPHI, and MRK LONDON, UK / ACCESSWIRE / May 15, 2018/ If you want a free Stock Review on PFE sign up now at www.wallstequities.com/registration . This morning, WallStEquities.com recalls the recent performance of four Major Drug Manufacturers, particular...
Source: ACCESSWIRE IA
Date: May, 15 2018 08:00
Your Daily Pharma Scoop: Omeros Up On Update, Synergy Sales, President's Healthcare Plans
Analysis focus: OMER Omeros (NASDAQ: OMER ) is moving towards a rolling BLA submission for OMS721. On this good news, and despite tepid Q1 results, investors are becoming increasingly bullish the stock, as seen by its sudden 23% spike on the news of the BLA submission. OMS721 is in tri...
Source: SeekingAlpha
Date: May, 14 2018 10:00
AstraZeneca Sees A Phase 3 Flop, But Not All Is Lost
Recently, it was announced that AstraZeneca ( AZN ) had failed a phase 3 study treating patients with chronic obstructive pulmonary disease (COPD). This is a huge blow to the big pharma, but not all is lost because it still has another shot on goal for this indication from another phase 3 st...
Source: SeekingAlpha
Date: May, 14 2018 01:50
Week In Review: $3.4 Billion Week For China Life Science Deals
Deals and Financings Armo BioSciences (ARMO), a Bay Area immuno-oncology company, agreed to be acquired by Eli Lilly (LLY) in a $1.6 billion transaction. Last year, Armo raised $67 million in a 2017 Series C-1 funding from China investors. Four months ago, Armo completed a $128 million IPO...
Source: SeekingAlpha
Date: May, 13 2018 11:40
AstraZeneca's benralizumab flunks late-stage COPD study
AstraZeneca (NYSE: AZN ) announces that a Phase 3 clinical trial, GALATHEA , evaluating asthma med Fasenra (benralizumab) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) failed to demonstrate a statistically valid decrease in exacerbations, the primary e...
Source: SeekingAlpha
Date: May, 11 2018 08:36
3 Things In Biotech, May 10: AstraZeneca Expands, Roche Digs In, OncoSec Gets A Collab
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a...
Source: SeekingAlpha
Date: May, 11 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1736.6336.4436.7436.185,134,529
2017-11-0733.6133.6133.69533.384,409,593
2017-11-0634.3334.2234.3534.123,390,584
2017-11-0334.2134.4834.5434.182,924,097
2017-11-0234.2934.1134.3734.033,234,366

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1510,731386,4262.7770Cover
2018-08-142,52859,1404.2746Cover
2018-08-138,85254,42816.2637Cover
2018-08-1019,68944,88043.8703Short
2018-08-0926,06660,95942.7599Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AZN.


About AstraZeneca Plc (NYSE: AZN)

Logo for AstraZeneca Plc (NYSE: AZN)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $23,027,175,517 - 05/11/2018
  • Issue and Outstanding: 632,614,712 - 12/31/2016

 


Recent Filings from (NYSE: AZN)

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 11 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 08 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 07 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 04 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: May, 01 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 27 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 24 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 19 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 13 2018
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act
Filing Type: 6-KFiling Source: edgar
Filing Date: April, 13 2018

 

 


Daily Technical Chart for (NYSE: AZN)

Daily Technical Chart for (NYSE: AZN)


Stay tuned for daily updates and more on (NYSE: AZN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NYSE: AZN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AZN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of AZN and does not buy, sell, or trade any shares of AZN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/